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Patients with decompensated liver cirrhosis have signiﬁcantly impaired synthetic function. Many proteins involved in the
coagulation process are synthesized in the liver. Routinely performed tests of the coagulation are abnormal in patients with
decompensated liver cirrhosis. This has led to the widespread belief that decompensated liver cirrhosis is prototype of acquired
hemorrhagic coagulopathy. If prothrombin time is prolonged more than 3 seconds over control, invasive procedures like
liver biopsy, splenoportogram, percutaneous cholangiography, or surgery were associated with increased risk of bleeding, and
coagulopathy should be corrected with infusion of fresh frozen plasma. These practices were without any scientiﬁc evidence and
wereassociatedwithsigniﬁcanthazardsoffreshfrozenplasmatransfusion.Now,itisrealizedthatcoagulationisacomplexprocess
involving the interaction of procoagulation and anticoagulation factors and the ﬁbrinolytic system. As there is reduction in both
anti and procoagulant factors, global tests of coagulation are normal in patients with acute and chronic liver disease indicating that
coagulopathy in liver disease is more of a myth than a reality. In the last few years, surgical techniques have substantially improved,
and complex procedures like liver transplantation can be done without the use of blood or blood products. Patients with liver
cirrhosis may also be at increased risk of thrombosis. In this paper, we will discuss coagulopathy, increased risk of thrombosis, and
their management in decompensated liver cirrhosis.
1.Introduction
Traditionally decompensated liver cirrhosis has been consid-
ered as a prototype of hemorrhagic coagulopathy. Routinely
performed coagulation proﬁle is abnormal in the majority of
these patients [1]. If prothrombin time is prolonged more
than 3 seconds over control, invasive procedures like liver
biopsy, splenoportogram, percutaneous cholangiography, or
surgery were associated with increased risk of bleeding [2].
For years, it was evident that haemostasis tests performed in
peripheral blood correlated poorly with the actual duration
of bleeding and the amount of blood loss measured directly
at laparoscopy from biopsy puncture. Abnormal bleeding
after liver biopsy is a random event which cannot be pre-
dicted by currently used coagulation tests. Abnormal coag-
ulation tests also did not correlate with development of
soft tissue hematomas, variceal bleeding, and other bleeding
episodes in cirrhotic patients [3–6].
In the recent years, surgical techniques have improved
remarkably, and even liver transplantation can be performed
without using blood or blood products [7]. It has been real-
ized that thrombin plug formation is a dynamic process, and
coagulation tests suggest that prothrombin time (PT) and
activated partial thromboplastin time (APTT) explore only
early phase of thrombin formation [8]. Thrombin formation
is globally measured by using a thrombin generation assay
modiﬁed by addition of thrombomodulin, and hence it is
sensitive not only to the low plasma level of coagulation
factors but also to the reduced levels of naturally occurring
coagulation inhibitors in patients with liver disease. Patients
with cirrhosis do form thrombin in amounts similar to
healthy individuals [9]. Two single-theme conferences have2 International Journal of Hepatology
beenorganized toaddress theissueof coagulationin patients
with liver cirrhosis, and the reports of both meetings have
been published [10, 11].
Both these reports suggest that coagulopathy in liver cir-
rhosis is a complex issue, and optimal strategies for predic-
tion and prevention of bleeding episodes cannot be done by
currently used coagulation tests and infusion of fresh frozen
plasma. Strategies to treat bleeding complications in decom-
pensated liver cirrhotic patients are not clear and require
further clinical studies [10, 11]. The proper management of
coagulopathy in patients with decompensated liver cirrhosis
is highly debatable, and a major area of interest in the ﬁeld
of hepatology in this paper, the physiology of normal coagu-
lation, the limitations of coagulation tests, and a reasonable
approach to the management of coagulation disorders in pa-
tients with decompensated liver disease will be discussed.
2. Coagulation and Haemostatic Abnormalities
inContextof DecompensatedLiverCirrhosis
Coagulation and heamostasis is a dynamic process with in-
terplay between primary heamostasis, coagulation, and ﬁb-
rinolysis. Majority of plasma clotting factors and proteins
of the ﬁbrinolytic and anticoagulants are synthesized in the
liver, while cell surface factors (surface factor is a trans-
membrane protein that acts as a receptor and cofactor for
FVII) responsible for heamostasis are not synthesized by
liver. Normal coagulation system has been conceptualized
as Y shape pathway with separate intrinsic and extrinsic
component initiated factor XII or factor VIIa/tissue factors
leading to a common pathway of factor Xa/factor Va. In
patients with severe liver disease, heamostasis is aﬀected
due to diminished synthesis of factors II, V, VI, IX, X, XI,
XIII, ﬁbrinogen, protein C, protein S, Vitamin K deﬁciency
due to malabsorption or malnutrition, dysﬁbrinogenemia,
enhanced ﬁbrinolysis, diﬀuse intravascular coagulation,
thrombocytopenia, impaired clearance of activated clotting
factors, plasminogen activators, and ﬁbrinogen degradation
products. Clinical consequences of this may lead to abnor-
mal bleeding test, bleeding, and thrombosis. Coagulation
in patients with decompensated liver cirrhosis can also
be aﬀected by other factors like infections, endogenous
heparinoids, renal failure, and endothelial dysfunction [10–
12]. Endogenous heparinoids have eﬀect on coagulopathy
in patients with cirrhosis. This has been demonstrated by
thromboelastography with addition of heparinase 1 in pa-
tients who have recent variceal bleed or infection. Eﬀect of
endogenous heparinoids has also been seen after reperfusion
of liver undergoing liver transplant patient [12].
Current concept of heamostasis is cell based. Primary
heamostasis initiates from the adhesions of circulating plate-
lets to the subendothelium at the site of injury through the
mediation of the adhesive protein von Willebrand factor
(VWF)andspeciﬁcplateletreceptors.ElevatedlevelsofVWF
seen in patients with cirrhosis are due to thrombocytopenia
and decreased VWF protein, cleaving protease ADAMTS13
[13, 14]. After the adhesions, platelet aggregation due to ﬁ-
brinogen or VWF with substances secreted by platelets
themselves act as agonist. Activated platelets express their
cell surface phosphatidylserine (P-serine) that promotes the
conversion of factor II to thrombin by means of factor
Xa, Va, and calcium. This is the initiating phase of a
chain of events leading to thrombin generation and ﬁnal
conversion of ﬁbrinogen to ﬁbrin. Fibrin is stabilized factor
XIII, and ﬁbrinolysis is responsible for degradation of ﬁbrin
through a complex mechanism of pro- and antiactivators
which regulates the generation of plasmin. Majority of the
factors involved in heamostasis, coagulation, ﬁbrinolysis,
and anticoagulation are synthesized in the liver. In normal
individuals, these systems are in a balance. In patients
with cirrhosis, VWF plays a key role together with fac-
tor IX and negatively charged phospholipids of activated
platelets to boost thrombin generation. Protein C activation
by thrombin in complex with its endothelial receptor
thrombomodulin acts as a powerful thrombin quenching
protease by inhibiting the activated form of factor V and
VIII. Patients with cirrhosis have increased levels of factor
VIII and decreased levels of protein C and antithrombin.
Elevation in factor VIII levels is due to decreased clearance
from the circulation [8]. There are patients with isolated
factor deﬁciencies like hemophilia and patients present with
bleeding in contrast to patients with liver disease who have
decreased levels of procoagulants and anticoagulants leading
to a balance in the heamostasis without increasing the risk of
bleeding,butthisbalanceisprecariousandmaybetippedoﬀ
either towards the bleeding or thrombosis by external factors
like infection, renal failure, and so forth [11, 15].
Another important factor in coagulation in patients
with decompensated liver cirrhosis is platelets. Patients with
decompensated liver cirrhosis have thrombocytopenia and
thrombocytopathy. This can be due to platelets seques-
tration, thrombopoietin deﬁciency, (myelosuppression due
to hepatitis C, folate deﬁciency, and ethanol toxicity)
autoantibodies, and low-grade disseminated intravascular
coagulation (DIC) [16–18]. Standard diagnostic tests of
platelet functions are of little use to predict the bleeding risk
in patients with liver disease. Decrease in platelet function
in cirrhosis is compensated by high plasma levels of VWF
which compensates for platelet capacity to provide surface
for thrombin generation. Platelet count beyond 50,000/mmq
is adequate enough for a normal heamostasis. Prophylactic
role of platelet transfusion is highly questionable [9].
2.1. Fibrinolysis and Liver Disease. Cirrhosis is considered to
be a hyperﬁbrinolytic state. The ﬁbrinolytic system consists
of plasminogen which is converted to plasmin via intrinsic
activation with factor XIIa, kallikrein, tissue plasminogen
activator (tPA), and urokinase. All these factors are syn-
thesized by the liver. Recent work has suggested that throm-
bin-activated ﬁbrinolysis inhibitor (TAFI) is decreased in
liver cirrhosis. Decrease in TAFI is counterbalanced by the
concomitantdecreaseinproﬁbrinolyticfactors,andexcessive
ﬁbrinolysis does not occur in patients with liver disease.
Various tests are available for assessing ﬁbrinolysis, and these
include (1) clot lysis time, (2) euglobulin lysis time, (3)
D-dimer assay, (4) ﬁbrinogen degradation product assay,International Journal of Hepatology 3
Table 1: Therapeutic options in coagulopathy in decompensated liver cirrhosis.
Agent Utility in speciﬁc situations Comment
Red blood cell transfusion Bleeding patients Transfusion should be minimum, not allowing
Hb to exceed 8 to 9mg%
Vitamin K Every patient May not be useful if patient has no deﬁciency
Fresh frozen plasma Questionable in bleeding patients May be used in bleeding patients when volume
expansion is not a concern
Platelets Count less than 50.000 Limited data
Cryoprecipitate In bleeding patients Limited data
Prothrombin complex concentrate In bleeding patients Limited data
Desmopressin In bleeding patients Eﬃcacy unproved
Aprotinin, transexamine acid, and
epsilon amino caprioric acid
Patients with hypoﬁbrinogenemia
Fibrinogen less than 100/dL Can induce thrombosis
Recombinant factor VII In placing ICP devices, bleeding
after surgery, massive variceal bleed Can induce thrombosis
Topical agents—cyanoacrylates, ﬁbrin
glue, and thrombin
Topical heamostasis and localized
bleeding Extremely expensive and limited data
Reduction in the portal pressure,
maintaining low CVP by volume
contraction (phlebotomy/diuresis)
Surgical techniques—vascular clamping,
ultrasonic/hydrojet dissectors, and
thermal techniques (aarton plasma
coagulator, radio frequency ablators)
(5) tPA assay, and (6) thromboelastogram clot lysis index.
Majority of these tests have high interindividual variability
and low speciﬁcity. Except for thromboelastogram, no com-
mercial test evaluates global ﬁbrinolysis. Measurement of in-
dividual components of the ﬁbrinolytic pathway is unlikely
to help in assessing and managing bleeding risk of cirrhosis
[19].
2.2. Clinical Tests for Coagulation in Liver Disease. Av a r i e t y
of coagulation of tests which include bleeding time, clotting
time, prothrombin time, activated partial thromboplastin
time, thrombin time, whole blood clot lysis, plasma ﬁb-
rinogen, serum ﬁbrinogen degradation product, plasma D-
dimer, euglobulin lysis time, factor assays for F XIII, protein
C, protein S, and antithrombin III. The literature evidence
suggests that conventional coagulation tests are of little value
in predicting bleeding risk in patients with cirrhosis and
are of limited use in guiding decisions of the appropriate
management of bleeding events in cirrhosis. For judging
the risk of bleeding, we need tests for global evaluation
of coagulation-like thrombin generation time, thromboe-
lastography, sonorheometry, and national normalized ratio
calibrated for cirrhosis (INRliver). Thrombin generation test
is a global test in which coagulation cascade is activated with
small amounts of tissue factor as a trigger and phospholipids
acting as a platelets substitute. Thrombin generation mea-
sured in the presence of thrombomodulin and platelet-rich
plasma is similar for patients with chronic liver disease and
healthy subjects. The critical platelet count is 60,000/cumm
[9, 20]. Thromboelastography measures clot formation, clot
strength, and clot dissolution but does not measure vascular
tone. It accesses global heamostasis. The modern throm-
boelastography which combines new computer technology
withnewmaterialsandequipmentispopularduringsurgical
interventions like liver transplantation [21]. The INR liver
is prothrombin time calibrated using plasma from patients
with cirrhosis instead of vitamin K antagonists and may
resolve variability of INR in these patients [22]. These tests
have not been prospectively evaluated in patients with liver
disease. Prothrombin time has been used traditionally in
assessmentofseverityofliverdiseaseinchildpughscoreoras
aINRinMELDscore.ProthrombintimeexpressedasanINR
is highly variable and hasnever been standardized in patients
with liver disease [20, 21]. Current controversies in patients
with liver cirrhosis are which humoral or hematological test
can predict risk of bleeding versus risk of thrombosis and
which prophylactic intervention can be used eﬀectively from
both bleeding and thrombotic perspective. Recently, Tripodi
et al. described a simple laboratory method which focuses
on function of protein C deﬁciency which could promote
clotting in patients of cirrhosis. This test is standardizable
laboratory test which may determine the relative risk of
clotting versus bleeding in patients with cirrhosis [23].
3. Management of Coagulopathy in
Decompensated LiverCirrhosis
VitaminKdeﬁciencyisseenindecompensatedlivercirrhosis
secondary to various complex mechanisms which include
bilesaltdeﬁciency,bilesaltsecretoryfailure,anduseofbroad
spectrum antibiotics. 10mg of vitamin K injections for three
days is adequate enough to correct the vitamin K deﬁciency4 International Journal of Hepatology
and should be given to patients with decompensated liver
cirrhosis. Oral vitamin K has no role [1]. Prophylactic cor-
rection of prothrombin time using fresh frozen plasma is not
recommended [22]. Prothrombin times more than4 seconds
over control are unlikely to get corrected with fresh frozen
plasma. Fresh frozen plasma has unpredictable response in
patients with decompensated liver cirrhosis and is associated
with signiﬁcant side eﬀects like volume overload, exacerba-
tion of portal hypertension, risk of infections, and risk of
transfusion-related acute liver injury [7].
4. Management of BleedingEpisodes
Patients with bleeding should be investigated for superim-
posed causes of coagulopathy like infections, renal failure,
and so forth. Superimposed insults should be corrected ag-
gressively. Other therapeutic options are as shown in Table 1.
Use of vitamin K has already been discussed. Platelet
transfusion may be considered if platelet count is less
than 50,000/mm3. Target platelet count to be achieved
is more than 70,000/mm3. Fresh frozen plasma contains
all coagulation factors, inhibitors of coagulation, and ﬁb-
rinolytic factors. Fresh frozen plasma should be solvent
detergent-treated plasma or donor-retested plasma. Thera-
peutic improvement is transient and may be associated with
adverse reactions as mentioned above. Hypoﬁbrinogenemia
(ﬁbrinogen <10mg/dL) should be treated with cryopre-
cipitate till normal ﬁbrinogen levels are reached. Other
agents used in the treatment of ﬁbrinolysis in patients with
decompensated liver cirrhosis are aprotinin, transexaminc
acid, and epsilon amino caproic acid. These agents play
a major role in treating local bleeding but also carry a
risk of thrombotic complications. Their use has not been
well studied in clinical trials. Desmopressin (DDAVP) is
an analogue of anti diuretic hormone vasopressin. DDAVP
releases vWf and factor VIII. It shortens the bleeding time,
and peak response is achieved in 30–60 minutes after
intravenous administration. Unfortunately, no beneﬁt of
DDAVP administration is seen in patients with variceal
bleedingandliversurgery.RecombinantactivatedfactorVIIa
is shown to improve prothrombin time and clot formation
without enhanced ﬁbrinolysis. The eﬀect is immediate but
transient. Repeated dosing is required and is extremely
expensive. Recombinant factor VIIa though clearly corrects
in vitro coagulation abnormalities was not shown to be
eﬀective in patients with variceal bleeding. Some advantage
was shown in child C cirrhosis. The most eﬃcient use of
this product is in intracranial pressure monitor placement. It
may have eﬃcient role in controlling active variceal bleeding
when there is no clear endoscopic view. Caveats with use of
recombinant factor Va are thrombotic complications, high
cost of the therapy, and limited outcome data. Control of
bleeding can be achieved with topical haemostatic agents like
ﬁbrin glue, cyanoacrylates, thrombin, and suture supports.
Surgical and anesthesiological methods used to reduce
the blood loss during liver surgery in patients with cirrhosis
are vascular clamping techniques, dissection devices like ul-
trasonic dissection, hydro jet dissection, thermal devises like
argon plasma coagulator and radio frequency ablator, and
topical haemostatic agents. Maintaining low central venous
pressure and reducing the portal pressure may also be of help
in controlling the bleeding during surgery [7, 8, 11].
Deep vein thrombosis, pulmonary embolism, and acute
portal vein thrombosis can be treated with anticoagulants
with special care [10]. Anticoagulation may prove to be safe
and eﬀective in patients with cirrhosis. Currently, antico-
agulation has been used in patients with portal vein throm-
bosis and if thrombosis has extended to superior mesenteric
vein. These patients are not suitable for liver transplantation.
A recent randomized control trial has shown that low-
molecular-weight heparin can prevent portal vein thrombo-
sis and cirrhosis [24, 25].
In summary, heamostasis in patients with decompen-
sated liver disease is a complex issue with counteracting for-
ces which are in dynamic equilibrium and are aﬀected
by extraneous factors like infection and renal function.
Currently, available tests for coagulation have a poor pre-
dictability for bleeding or thrombosis in patients with
cirrhosis. New tests like TEG, thrombin tests, and so forth
may give a better picture but need prospective studies. Role
of speciﬁc intervention like platelet transfusion, antiﬁbri-
nolytics and recombinant factors, anticoagulant need to be
deﬁned clearly.
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